Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Total Current Liabilities (2016 - 2026)

Ovid Therapeutics filings provide 11 years of Total Current Liabilities readings, the most recent being $15.7 million for Q1 2026.

  • Quarterly Total Current Liabilities rose 69.21% to $15.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $15.7 million through Mar 2026, up 69.21% year-over-year, with the annual reading at $8.3 million for FY2025, 21.23% down from the prior year.
  • Total Current Liabilities hit $15.7 million in Q1 2026 for Ovid Therapeutics, up from $8.3 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $15.7 million in Q1 2026 and bottomed at $6.7 million in Q1 2023.
  • Average Total Current Liabilities over 5 years is $9.9 million, with a median of $9.1 million recorded in 2025.
  • The largest annual shift saw Total Current Liabilities crashed 52.75% in 2022 before it soared 69.21% in 2026.
  • Ovid Therapeutics' Total Current Liabilities stood at $7.0 million in 2022, then surged by 64.1% to $11.5 million in 2023, then fell by 8.29% to $10.5 million in 2024, then decreased by 21.23% to $8.3 million in 2025, then skyrocketed by 90.01% to $15.7 million in 2026.
  • Per Business Quant, the three most recent readings for OVID's Total Current Liabilities are $15.7 million (Q1 2026), $8.3 million (Q4 2025), and $6.8 million (Q3 2025).